Get started
Author

Francesca Bergamo

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
2025 · P. Ciracì, M.M. Germani, et al. · Annals of Oncology · 20
PDF
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
2025 · F. Piscaglia, G. Masi, et al. · ESMO Open · 18
PDF
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
2025 · C. Antoniotti, M. Carullo, et al. · ESMO Open · 16
Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer
2016 · Maria Di Bartolomeo, Filippo Pietrantonio, et al. · Tumori Journal · 13
509O Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial
2024 · A. Amatu, M.G. Zampino, et al. · Annals of Oncology · 12
PDF
59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
2022 · M. Borad, M. Javle, et al. · Annals of Oncology · 12
PDF
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience
2024 · R. Moretto, M.M. Germani, et al. · ESMO Open · 11
PDF
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
2023 · M. Reni, E. Giommoni, et al. · ESMO Open · 10
PDF
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients
2025 · A. Pretta, V. Nasca, et al. · ESMO Open · 7
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO
2025 · M.M. Germani, V. Heinemann, et al. · Annals of Oncology · 5
PDF
370P Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial
2022 · A. Sartore Bianchi, S. Lonardi, et al. · Annals of Oncology · 5
LBA22 Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
2022 · C. Pinto, A. Orlandi, et al. · Annals of Oncology · 5
IMMUNOREACT 4: Peritumoral Microenvironment Associated with Anastomotic Leaks After Surgery for Rectal Cancer
2026 · Ottavia De Simoni, Melania Scarpa, et al. · Cancers · 4
PDF
185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
2023 · F. Rossari, T. Tada, et al. · Annals of Oncology · 4
PDF
44P Rechallenge with anti-HER2 regimens in metastatic colorectal cancer: The retrospective RHEA study
2025 · A. Sartore Bianchi, G. Mauri, et al. · Annals of Oncology · 3
PDF
725O Leveraging artificial intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: Translational analyses of AtezoTRIBE and AVETRIC trials
2025 · M. Carullo, C. Antoniotti, et al. · Annals of Oncology · 2
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
2025 · R. Fazio, G. Randon, et al. · ESMO Open · 2
PDF
423P Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study
2024 · A. Raimondi, S. Lonardi, et al. · Annals of Oncology · 2
PDF
SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
2023 · M. Germani, R. Moretto, et al. · Annals of Oncology · 2
PDF
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine–nab-paclitaxel failure: a propensity score-matched analysis
2025 · G. Trovato, D. Rossini, et al. · ESMO Open · 1
PDF
114P Radiologist concordance and pathology correlation in non metastatic colon cancer (NMCC) staging
2025 · G. Randon, G. Tinè, et al. · Annals of Oncology · 1
Comment on: “Risk of distant metastasis after local excision for near-complete response versus salvage surgery for local regrowth in rectal cancer: Results from an international registry”
2025 · Quoc Riccardo Bao, Lorenzo Dell’Atti, et al. · European Journal of Surgical Oncology · 1
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)
2025 · M. Reni, M. Milella, et al. · ESMO Open · 1
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey
2024 · M. Reni, E. Giommoni, et al. · Pancreatology · 1
56P Systemic inflammation in liver vs non-liver metastatic microsatellite stable (MSS) colorectal cancer (CRC): An analysis of 2186 patients (pts) from the observational study BMI-QoL and the phase II and III trials MACBETH, MOMA, ATEZOTRIBE, TRIBE, TRIBE2, TRIPLETE
2024 · V. Formica, C. Cremolini, et al. · Annals of Oncology · 1
PDF
Works count: 65
Citation count: 162
H-index: 8
I10-index: 8
Year
Topic
Type